| Title: |
FAIRplus use case IMI CARE: Quick-response COVID-19 effort opens FAIR data on ~5,500 compounds |
| Authors: |
Custers, Ilse; Boutsma, Erwin; Boiten, Jan-Willem; Duyndam, Alexander; Xu, Fuqi; Juty, Nick; Gribbon, Philip |
| Publisher Information: |
Zenodo |
| Publication Year: |
2022 |
| Collection: |
Zenodo |
| Subject Terms: |
FAIRplus; COVID-19; Innovative Medicines Initiative; EFPIA; FAIRdata |
| Description: |
The IMI CARE project was initiated in response to the COVID-19 pandemic with the goal to deliver treatments for COVID-19 and future coronavirus outbreaks. Started in April 2020, CARE not only focuses on delivering novel drugs designed specifically to treat COVID-19 and other coronaviruses, but also on ‘repurposing’ approved drugs and drug candidates that were originally developed for other diseases that could potentially treat COVID-19. By making CARE data public, it also helps other drug repurposing studies. The CARE project is sharing its scientific results through open-access platforms and peer-reviewed journals, as well as via relevant conferences and other events. Recently, in the context of the CARE project, Janssen Pharmaceutica published a dataset in the public domain describing the results of ~5,500 FDA-approved drugs and clinical candidates that have passed Phase I studies which were screened for anti-SARS-CoV-2 activity. The FAIRplus squad team supported the Janssen Pharmaceutica coronavirus discovery team to improve findability, interoperability, and reuse of the drug data. |
| Document Type: |
text |
| Language: |
unknown |
| Relation: |
https://zenodo.org/communities/eu/; https://zenodo.org/records/7441699; oai:zenodo.org:7441699; https://doi.org/10.5281/zenodo.7441699 |
| DOI: |
10.5281/zenodo.7441699 |
| Availability: |
https://doi.org/10.5281/zenodo.7441699; https://zenodo.org/records/7441699 |
| Rights: |
Creative Commons Attribution 4.0 International ; cc-by-4.0 ; https://creativecommons.org/licenses/by/4.0/legalcode |
| Accession Number: |
edsbas.CF2DC277 |
| Database: |
BASE |